Summary
The Frederick National Laboratory for Cancer Research (operated by Leidos Biomedical Research, Inc. on behalf of the National Cancer Institute) is soliciting vendor proposals for a service maintenance agreement covering four Nova Biomedical Bioprofile Flex 2 analyzers located at the NCI-Frederick campus. The contract requires Emerald Comprehensive coverage for one unit and Gold Comprehensive coverage for three units, covering preventive maintenance requirements over a one-year period of performance from September 15, 2026 through September 14, 2027. This is a commercial goods/services procurement (not a grant program) under NCI OA contract 75N91019D00024 (NCI-FFRDC), solicitation number M26-107, with contact person Cathy Goodman.